A Look At Neurocrine Biosciences (NBIX) Valuation As New INGREZZA Real World Data Gains Attention

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.

Why INGREZZA data matters for Neurocrine Biosciences stock

Neurocrine Biosciences (NBIX) has drawn fresh attention after presenting new real world clinician survey data on INGREZZA in mild tardive dyskinesia, highlighting reduced uncontrolled movements and better day to day functioning for treated patients.

For investors, this type of real world evidence helps link INGREZZA not only to symptom control but also to practical outcomes such as independence, daily activities and work participation. These factors often sit at the center of long term treatment decisions.

See our latest analysis for Neurocrine Biosciences.

That real world INGREZZA update lands while Neurocrine Biosciences’ share price, at US$154.67, sits on a 30 day share price return of 17.54% and a 1 year total shareholder return of 28.29%, suggesting recent momentum building on a multi year gain of 67.01% in total shareholder return.

If INGREZZA’s real world data has you thinking about where else treatment focused stories could emerge, it can be useful to see what other healthcare AI opportunities are screening well through 30 healthcare AI stocks

With INGREZZA’s new real world data, recent earnings strength and the Soleno deal all in focus, the key question now is simple: is Neurocrine Biosciences undervalued, or is the current share price already factoring in future growth?

Most Popular Narrative: 17% Undervalued

The most followed narrative puts Neurocrine Biosciences’ fair value at $186.45 per share versus the last close at $154.67, framing a meaningful potential valuation gap driven by INGREZZA and the broader pipeline.

A broad, late-stage and diversified CNS pipeline, including multiple Phase III programs targeting major depressive disorder and schizophrenia, leverages advances in precision medicine and increases visibility for future earnings, supporting potential future valuation multiple expansion.
Ongoing internal innovation in biologics (such as bispecifics, ADCs, peptides), and a strong preclinical pipeline, allows Neurocrine to capitalize on industry advancements in drug modalities, expanding the addressable market and supporting long-term revenue growth.

Read the complete narrative.

Want to understand why this narrative supports a higher price tag? It draws on assumptions of compound revenue growth, rising margins, and a richer earnings multiple in 2029 estimates. The valuation story sits in how those three elements are modeled to interact over time.

Story Continues

Result: Fair Value of $186.45 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this hinges on INGREZZA and CRENESSITY continuing to meet expectations, and any sustained pricing or reimbursement pressure could quickly challenge the upside case.

Find out about the key risks to this Neurocrine Biosciences narrative.

Another View: What The P/E Ratio Is Telling You

While the most popular narrative leans on detailed cash flow and earnings projections, the current P/E of 23.3x paints a different picture. It sits above the US Biotechs industry at 16.2x and above the 20.8x peer average, yet hovers close to the estimated fair ratio of 23.9x. This suggests less obvious upside and more room for debate on how much optimism is already in the price.

See what the numbers say about this price — find out in our valuation breakdown.NasdaqGS:NBIX P/E Ratio as at May 2026

Next Steps

With sentiment clearly split between upside potential and a full valuation, it makes sense to act quickly by reviewing the numbers yourself and testing the optimism behind 4 key rewards.

Looking for more investment ideas?

If Neurocrine Biosciences has sharpened your focus, do not stop here. Broaden your watchlist now so you are not chasing ideas after they break out.

Target companies the market may be overlooking by scanning for quality stocks trading below their estimated worth with the 51 high quality undervalued stocks. Strengthen your income stream by reviewing companies offering robust payouts through the 10 dividend fortresses. Reduce portfolio stress by focusing on sturdier balance sheets and steady fundamentals using the solid balance sheet and fundamentals stocks screener (46 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NBIX.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments